{"public_id":"cl_38c176787f724903f9609e8d1358b718","status":"active","superseded_by_public_id":null,"corpus_id":6793687,"text":"Rapid responses were common, with more than 14% of complete remissions and 66% of overall responses achieved with the first course of treatment.","confidence":0.92,"paper":{"corpus_id":6793687,"title":"Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma","url":"https://sah.borca.ai/papers/6793687"},"contributors":[{"id":1,"public_id":"12632b8b5f","public_label":"Anonymous (12632b8b5f)","roles":["extraction"],"url":"https://sah.borca.ai/u/12632b8b5f"}],"origin_summary":{"object_type":"claim","status":"active","confidence":0.92,"origin_kinds":["extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":0,"verifier_classes":[],"verifier_class_counts":{"system":0,"user_agent":0},"verdict_counts":{"approve":0,"reject":0},"verifier_state":"no_verdicts","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","claim.status","claim.confidence"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"concepts":[{"public_id":"co_4d1534db24cf29531bccd1e18a969425","name":"first course of treatment","description":"The initial chemotherapy cycle given at the start of induction therapy.","types":["treatment phase"],"url":"https://sah.borca.ai/concepts/co_4d1534db24cf29531bccd1e18a969425"},{"public_id":"co_920024d341e9de6606bc2e6ad6da3a94","name":"complete remission","description":"A treatment outcome in which no detectable disease remains.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_920024d341e9de6606bc2e6ad6da3a94"},{"public_id":"co_fcf57680d602fa324483db529a2d1600","name":"overall response","description":"The proportion of patients whose disease responded to treatment, including complete and partial responses.","types":["outcome"],"url":"https://sah.borca.ai/concepts/co_fcf57680d602fa324483db529a2d1600"}],"related_claims":[],"url":"https://sah.borca.ai/claims/cl_38c176787f724903f9609e8d1358b718"}